Recently, it has been shown that inhibition of GSK-3β resulted in increased suppression activity by Treg cells [16], suggesting GSK3β-mediated Treg insufficiency may be considered a therapeutic target for the management of asthma. The gene discussed is GSK3B; the disease is asthma.